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Abstract
Congenital adrenal hyperplasia (CAH) is a severe inherited disorder of cortisol biosynthesis
that is potentially lethal or can seriously affect quality of life. For the first time, we aimed to
assess the stability of 21-deoxycortisol (21Deox), 11-deoxycortisol (11Deox), 4-androstene-
dione (4AD), 17-hydroxyprogesterone (17OHP) and cortisol (Cort), diagnostic for CAH, in
dried blood spots (DBSs) during a 1 year storage at different temperatures. Spiked DBS
samples were stored at room temperature, 4 ˚C, -20 ˚C or -70 ˚C, respectively and analyzed
in triplicates using liquid chromatography–tandem mass spectrometry at Weeks 0, 1, 2, 3
and 4, Month 6 and Year 1. Analyte levels within ±15% vs the baseline were considered sta-
ble. Our observations show that 21Deox, 4AD and 17OHP were not significantly changed
for 1 year even at room temperature at either analyte levels. In contrast, Cort required stor-
age at 4 ˚C, -20 ˚C or -70 ˚C for long-term stability, being significantly decreased at room
temperature from Month 6 (p<0.01) in both the 30(60) nM and the 90(180) nM samples.
11Deox was significantly decreased at room temperature at Year 1 (p<0.01) and only in the
30(60) nM samples. Thus, all biomarkers were stable for up to 1 year at 4 ˚C, -20 ˚C or -70
˚C and at least for 4 weeks at room temperature. These findings have implications for analy-
ses of stored DBS samples in 2nd-tier assays in newborn screening and for retrospective
CAH studies.
Introduction
Congenital adrenal hyperplasia (CAH; OMIM 201910, OMIM 202010) is a severe inherited
disorder of cortisol biosynthesis [1,2]. The underlying enzyme defect can result in a disturbed
sodium homeostasis with hyponatremia and hyperkalemia which can cause death in early
infancy [1,2]. The accumulated steroid precursors are in part converted to androgens, which
can additionally cause prenatal virilization in affected girls and postnatal androgen excess in
both males and females, resulting in a markedly reduced quality of life [1,2].
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In order to achieve a timely diagnosis of this possibly lethal disorder, dried blood spots
(DBSs) [3] are used for the newborn screening (NBS) of CAH for the measurement of the
17-hydroxyprogesterone (17OHP) level by means of time-resolved, dissociation-enhanced,
lanthanide fluorescence immunoassay (DELFIA1) [1,2]. Due to the relatively high number of
false-positives and the resulting low positive predictive value in the 1st-tier testing, the confir-
mation of CAH with a second assay is necessary [1,2]. Second-tier testing using liquid chroma-
tography–tandem mass spectrometry (LC-MS/MS) is preferable which uses the same DBS
specimen as in the primary screening [1,2,4–6].
For this approach, it has to be assumed that steroid levels in the DBS specimen are suffi-
ciently stable and are representative for the time of blood sampling [7–9]. However, current lit-
erature on the stability of the steroids in DBS is very limited, dealing exclusively with 17OHP
[10–16] or cortisol (Cort) [17]. Data on the DBS stability of 21-deoxycortisol (21Deox) and
11-deoxycortisol (11Deox), which are specific biomarkers of the two main types of CAH, the
21-hydroxylase and 11β-hydroxylase deficiencies [1,2]; or that of 4-androstenedione (4AD)
have not been published yet.
Long-term stability data on these biomarkers could additionally extend the current knowl-
edge regarding the retrospective analysis of stored DBS samples. As an example, retrospective
analysis of NBS specimens from symptomatically diagnosed patients in countries without NBS
for CAH [18] could provide valuable information whether CAH would have already been
detected at newborn age. Such results could then be used as evidence to facilitate local health-
care providers to include CAH in the NBS panel. Moreover, retrospective analysis of stored
DBS may be an important tool in clarifying if a deceased child had been suffering from CAH
or not. This may promote awareness and family planning in affected families, which is consid-
ered as an important complementary outcome of NBS, in addition to the timely diagnosis of
affected children [19].
We therefore aimed to assess the time course of the potential alterations of five steroids,
diagnostic for CAH, during a 1 year storage in DBS. To elucidate possible effects of the storage
temperature, measurements were performed on specimens stored at room temperature, 4 ˚C,
-20 ˚C or -70 ˚C, respectively.
Materials and methods
Reagents
Unlabelled Cort, 21Deox, 11Deox, 4AD and 17OHP were purchased from Sigma-Aldrich
(St. Louis, MO, USA); deuterated internal standards (ISs) d4-Cort, d8-21Deox, d2-11Deox, d5-
4AD and d8-17OHP from Cambridge Isotope Laboratories (Andover, MA, USA); acetonitrile
(LC-MS grade) from Merck (Darmstadt, Germany); methanol (LC-MS grade) and formic acid
(LC-MS grade) from Honeywell (Charlotte, NC, USA). Ultrapure water (18.2 MO.cm), filtered
through a 0.22 μm pore size membrane, was obtained from a Merck Millipore Direct-Q 3 UV
system (Billerica, MA, USA).
Preparation of standard and IS stock, intermediate and working solutions
Unlabelled standards and deuterated ISs were dissolved in methanol separately to obtain 5
mM stock solutions. An intermediate solution mix of unlabelled standards was obtained by
mixing stock solutions and diluting with methanol/water 50/50 (v/v) to give final concentra-
tions of 5 μM each for 21Deox, 11Deox, 4AD and 17OHP and 10 μM for Cort (indicated as 5
(10) μM). An intermediate solution mix of deuterated ISs was obtained by mixing IS stock
solutions and diluting with methanol/water 50/50 (v/v) to give final concentrations of 100 nM
for d4-Cort, 75 nM for d8-21Deox and 15 nM each for d2-11Deox, d5-4AD and d8-17OHP.
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Stock solutions and intermediate solution mixes were stored in aliquots at -70 ˚C. The IS
working solution (composition: 10 nM d4-Cort, 7.5 nM d8-21Deox and 1.5 nM each of d2-
11Deox, d5-4AD and d8-17OHP) was prepared fresh daily by a 10-fold dilution of the interme-
diate solution mix of deuterated ISs with acetonitrile/water 80/20 (v/v).
Preparation of the DBS samples, duration and conditions of storage
Heparinized blood form a single healthy volunteer (author I.SZ.) was centrifuged at 1000 x g
for 15 min, and the erythrocytes were washed three times with phosphate-buffered saline
(serum and supernatant were discarded). The erythrocytes were mixed with commercially
available steroid-depleted serum (BBI Solutions, Crumlin, UK) to produce steroid-depleted
blood with a hematocrit of 50%. Thereafter, the steroid-depleted blood was subjected to three
freeze-thaw cycles at -70 ˚C to ensure homogeneity.
For the preparation of the calibrators, an aliquot of the steroid-depleted blood was spiked
with the intermediate solution mix of unlabeled standards to obtain a concentration of 250
(500) nM for steroids (Cort). Calibrators were prepared via mixing appropriate volumes of the
250(500) nM sample or the respective previous calibrator gently but thoroughly with steroid-
depleted blood. The 0(0) nM calibrator contained steroid-depleted blood without spiking.
Final concentrations of the DBS calibrators were as follows: 0(0), 2(4), 5(10), 10(20), 25(50), 75
(150) and 125(250) nM for steroids (Cort).
For the preparation of the QCs and test samples, aliquots of the steroid-depleted blood
were spiked with equal volumes of spiking solutions in saline (corresponds to a 100-fold dilu-
tion of the analytes) and mixed gently but thoroughly. Final concentrations of the QCs were
15(30), 30(60) and 90(180) nM for steroids (Cort), respectively. The spiked test samples were
prepared in levels 30(60) and 90(180) nM for steroids (Cort), respectively.
Thereafter, the samples were spotted onto Ahlstrom-Munksjö TFN filter paper cards (Ahl-
strom-Munksjö Germany GmbH, Bärenstein, Germany) and dried at room temperature for
24 h. All DBS calibrators, QCs and test samples were stored in sealed aluminium bags with sil-
ica gel desiccants. The calibrators and the QCs were stored at -70 ˚C and were used for the
quantification of all test samples, regardless of the storage temperature (room temperature, 4
˚C, -20 ˚C or -70 ˚C), in line with the paper of Elvers et al [14]. For test samples stored frozen,
repeated freeze-thaw cycles were avoided. Measurement time points (storage durations) were
Weeks 0, 1, 2, 3 and 4, Month 6 and Year 1. All test samples were prepared as triplicates at
each time point. Analytes remaining within ±15% vs the baseline were considered stable in
line with recommendations [20].
All procedures followed were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and national) and with the Helsinki Dec-
laration of 1975, as revised in 2000. The study was approved by the Ethical Committee of the
University of Szeged (139/2018-SZTE). The whole blood used for the preparation of the cali-
brators, QCs and spiked test samples originated from one of the authors (I.SZ.); therefore, no
written consent was obtained. However, information on study characteristics and possible
risks of blood sampling were verbally discussed among the authors beforehand and were docu-
mented in the internal protocol file.
Sample preparation and instrumentation
The sample preparation procedures have been published previously [21]. Briefly, two spots 4.7
mm in diameter (corresponding to approx. 13.6 μl blood) of each of the DBS calibrators, QCs
and test samples were extracted with the IS working solution for 45 min at ambient tempera-
ture in 96-well microtiter plates. Following centrifugation, the supernatant was transferred to a
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second microtiter plate and dried at 35 ˚C in a gentle flow of air for 45 min. The underivatized
residues were reconstituted in 45 μl of a methanol/water mixture (20:80 v/v). The levels of
Cort, 21Deox, 11Deox, 4AD and 17OHP were measured with a gradient LC-MS/MS method,
which had been previously validated using External Quality Control specimens and clinical
DBS samples with inter-day variabilities of approx. 10-15% [21]. The system consisted of a Per-
kinElmer Flexar UHPLC system (two FX-10 binary pumps, solvent manager with a degasser,
autosampler and thermostatic oven; all PerkinElmer Inc., Waltham, MA, USA), combined
with an AB SCIEX QTRAP 5500 MS/MS triple quadrupole mass spectrometer, and controlled
by Analyst 1.6.1 software (both AB SCIEX, Framingham, MA, USA). Chromatographic sepa-
ration was performed on a Phenomenex Kinetex XB-C18 100x3.0 mm, 2.6 μm core-shell ana-
lytical column and a SecurityGuard Ultra Cartridge guard column (both Phenomenex,
Torrance, CA, USA). Eluent A consisted of ultrapure water (18.2 MO.cm, filtered through a
0.22 μm pore size membrane) plus 0.1% formic acid (LC-MS grade). Eluent B consisted of
methanol plus 0.1% formic acid (both LC-MS grade). Results of the LC-MS/MS analysis are
reported in nM.
Statistical analysis
Statistical comparisons were performed by using repeated-measures two-way analysis of vari-
ance (ANOVA), followed by Dunnett’s multiple comparisons test, using GraphPad Prism soft-
ware (GraphPad Software, La Jolla, CA, USA). Results are reported as means±standard
deviation (SD). p values <0.01 were considered significant.
Results
21Deox in DBS was stable during the study period, regardless of the storage temperature. Also
17OHP remained within the predetermined ±15% range, apart from significantly elevated val-
ues at a single measurement point (Week 2) at room temperature in the 90(180) nM samples
(20% increase, p<0.01). When DBSs were stored at both -20 ˚C or -70 ˚C, Cort levels remained
within the range throughout the 1 year interval, despite a slight but non-significant decreasing
tendency in the 30(60) nM samples at both temperatures. However, in specimens stored at
room temperature, Cort concentrations became significantly lower than the cutoff at Month 6
and at Year 1 in both the 30(60) nM and the 90(180) nM samples (28% and 26% decrease at
Year 1, respectively; both p<0.01). At 4 ˚C, significantly lower Cort levels were measured only
in the 90(180) nM samples at Month 6 (25% decrease, p<0.01), but not at Year 1. 11Deox was
within the range for 1 year when stored at 4 ˚C, -20 ˚C or -70 ˚C, and was significantly
decreased at Year 1 at room temperature in the 30(60) nM samples (18% decrease p<0.01).
4AD concentrations remained in the range, apart from significantly elevated values at a single
measurement point (Week 4) at room temperature in both the 30(60) nM and the 90(180) nM
samples (19% and 21% increase at Year 1, respectively; both p<0.01) (Figs 1 and 2, S1 Table).
Using an external QC sample, variation during the 1-year study was found to be<9% for all
analytes (S1 Table).
Discussion
CAH is a severe and potentially life-threatening disorder where an early diagnosis is crucial for
a timely initiation of treatment. The stability of Cort, 4AD and 17OHP levels have been previ-
ously assessed in various sample matrices including plasma, serum, saliva, hair or urine [22–
26]. Storage durations in these studies ranged from 72h to 2 years; the storage temperature var-
ied from -70 ˚C to ambient [22–26].
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Fig 1. Steroid concentrations in the 30(60) nM test samples during storage within 1 year at different temperatures (n = 3 for
each data point). Values are given as means±SD. Cort: cortisol; 21Deox: 21-deoxycortisol; 11Deox: 11-deoxycortisol; 4AD:
4-androstenedione; 17OHP: 17-hydroxyprogesterone; RT: room temperature. Dashed red lines indicate upper and lower cutoffs of the
predetermined ranges (±15% vs Week 0), within which analytes were considered stable. � p<0.01 vs the baseline at room temperature.
Error bars for SD values smaller than the respective symbol size are not visible.
https://doi.org/10.1371/journal.pone.0233724.g001
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Fig 2. Steroid concentrations in the 90(180) nM test samples during storage within 1 year at different temperatures (n = 3 for
each data point). Values are given means±SD. Cort: cortisol; 21Deox: 21-deoxycortisol; 11Deox: 11-deoxycortisol; 4AD:
4-androstenedione; 17OHP: 17-hydroxyprogesterone; RT: room temperature. Dashed red lines indicate upper and lower cutoffs of the
predetermined ranges (±15% vs Week 0), within which analytes were considered stable. � p<0.01 vs the baseline at room temperature;
† p<0.01 vs the baseline at 4 ˚C. Error bars for SD values smaller than the respective symbol size are not visible.
https://doi.org/10.1371/journal.pone.0233724.g002
PLOS ONE Storage stability of five steroids in DBS for diagnosis of CAH
PLOS ONE | https://doi.org/10.1371/journal.pone.0233724 May 29, 2020 6 / 10
NBS for CAH is performed in several countries to facilitate early recognition, treatment
and the prevention of serious morbidity and mortality [1,2]. However, the DBS, not plasma,
serum, saliva, hair or urine, is the standard sample type in NBS [8,9]. A very limited number of
papers on stability in DBS are available, evaluating 17OHP [10–16] or Cort [17]. There have
been no reports on the stability of 21Deox, 11Deox or 4AD in DBS. According to the literature,
17OHP in DBS is stable for at least one year at room temperature [10–13] or for up to 2 years
when stored frozen at -20 ˚C or -80 ˚C [14] or at 4 ˚C [15]. Using forced degradation at 37 ˚C,
17OHP was already decreased after 1 month [16]. The only paper on Cort in DBS reported
that Cort from a single healthy volunteer remained unchanged after 1 month at room tempera-
ture [17]. Of note, the analytical techniques in these previous studies (radioimmunoassay,
DELFIA, HPLC-diode array detection) are reportedly prone to cross-reactions and/or have
relatively low selectivities [2,27] when compared with LC-MS/MS, which is the technique of
choice for the determination of steroids in CAH [1,2,4–6].
The present study is the first to evaluate the stability of 21Deox, 11Deox or 4AD in DBS,
together with Cort and 17OHP using a clinically validated LC-MS/MS method [21]. 21Deox
was found to be stable throughout the 1 year study period, regardless of both the storage tem-
perature and the concentration (Figs 1 and 2). 11Deox was also stable for 1 year at 4 ˚C, -20 ˚C
or -70 ˚C; a significant decrease was only seen at room temperature at Year 1 and only in the
30(60) nM samples (p<0.01) (Figs 1 and 2). These new findings are important in the view that
21Deox (produced from the 11β-hydroxylation of 17OHP) and 11Deox are specific biomark-
ers of the two main subtypes of CAH, the 21-hydroxylase and 11β-hydroxylase deficiencies
which account for>99% of all cases [1,2,4].
17OHP, the 1st-tier biomarker in CAH screening, was stable in DBS for 1 year (Figs 1 and
2), in line with previous studies [10–15]. 4AD concentrations were within the allowed range
prior to and after Week 4 (Figs 1 and 2). Thus, elevated values of 4AD at Week 4 at both ana-
lyte levels, as well as higher 17OHP concentrations at Week 2 in the 90(180) nM samples seem
to be only of statistical significance, rather than a sign of a real alteration with clinical rele-
vance. Cort levels, when stored frozen at -20 ˚C or -70 ˚C, remained within the range in the
study period despite an apparent slight decrease in the 30(60) nM samples. However, when
stored at room temperature, Cort became significantly lower than the cutoff at Months 6 and
12 at both analyte levels. At 4 ˚C, lower Cort levels were only seen in the 90(180) nM samples
and solely at Month 6, but not at Year 1, suggesting that this may be due to casual variation
(Figs 1 and 2). Such random analytical alterations may reportedly be correctable by the appli-
cation of ISs directly onto the filter paper. This approach has been described in previous papers
for analytes other than steroids [28–30].
Further limitations of the present study include the relatively low number of replicates and
the fact that more measurement time points would have allowed following the alterations
more precisely. Even if an additional measurement had been planned for Month 3, a reliable
acquisition was not possible due to an instrument breakdown and lengthy service process. In
addition, stability testing of real patient samples should be considered in the future to elucidate
other potential confounding factors such as steroid-binding proteins [31], despite the relatively
large amount of blood necessary for prolonged storage experiments. Our results are suggested
to be confirmed by the individual laboratories in their own settings, together with the assess-
ment of potentially confounding factors, such as temperature and humidity [16].
One clinical implication of the present study is that the examined biomarkers of CAH are
now proved to be stable in DBS for at least 4 weeks, allowing sufficient time to use NBS sam-
ples, generally stored at room temperature [9], in 2nd-tier assays and re-testing in the short-
term. Second-tier testing is commonly performed within 7 days from blood sampling, whereas
the salt-wasting phenotype of CAH normally presents within 2-3 weeks of age without timely
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diagnosis and treatment [32]. Although similar time frames arecommonly used in NBS for
CAH, there have been no previous reports with experimental evidence on their appropriate-
ness. For long-term storage (>4 weeks), suspected or confirmed patient samples are suggested
to be stored frozen at -20 ˚C or -70 ˚C to allow for using them in method development, patient
monitoring and quality assurance purposes.
Furthermore, our stability results extend the current knowledge regarding the retrospective
analysis of stored DBS samples, including those from symptomatically diagnosed patients in
countries without NBS for CAH [18]. Such results may facilitate local healthcare providers to
include CAH in the NBS panel, as well as promote awareness and family planning in affected
families [19]. However, these assumptions have to be confirmed via retrospective analysis of
real patient samples.
Conclusions
For the first time, storage stabilities of 21Deox, 11Deox, Cort, 4AD and 17OHP levels were
simultaneously evaluated in DBS using a clinically validated LC-MS/MS method. Experimen-
tal evidence is provided that the assessed biomarkers are stable for at least 4 weeks even at
room temperature, allowing sufficient time to use NBS samples in 2nd-tier assays and re-test-
ing. As concerns long-term storage for up to 1 year, concentrations of 21Deox, 4AD and
17OHP were found to be stable. Cort and 11Deox levels remained within the ±15% range
when stored at 4 ˚C, -20 ˚C or -70 ˚C. Cort was decreased at Months 6 and 12 when stored at
room temperature. 11Deox was decreased at Month 12 at room temperature only in the 30
(60) nM samples. These new findings have implications for analyses of stored DBS samples in
2nd-tier assays in NBS and for various retrospective studies on CAH.
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